

Natasha Szuber

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7898822/natasha-szuber-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

46
papers

570
citations

11
h-index

23
g-index

48
ext. papers

848
ext. citations

5
avg, IF

3.99
L-index

#	Paper	IF	Citations
46	and dominate clonal hematopoiesis and demonstrate benign phenotypes and different genetic predispositions. <i>Blood</i> , 2017 , 130, 753-762	2.2	178
45	Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera. <i>British Journal of Haematology</i> , 2020 , 189, 291-302	4.5	58
44	Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1,095 patients. <i>American Journal of Hematology</i> , 2018 , 93, 348-355	7.1	54
43	3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups. <i>Mayo Clinic Proceedings</i> , 2019 , 94, 599-610	6.4	50
42	Mutations and prognosis in myelodysplastic syndromes: karyotype-adjusted analysis of targeted sequencing in 300 consecutive cases and development of a genetic risk model. <i>American Journal of Hematology</i> , 2018 , 93, 691-697	7.1	34
41	Myeloproliferative neoplasms in the young: Mayo Clinic experience with 361 patients age 40 years or younger. <i>American Journal of Hematology</i> , 2018 , 93, 1474-1484	7.1	31
40	Splanchnic vein thrombosis in patients with myeloproliferative neoplasms: The Mayo clinic experience with 84 consecutive cases. <i>American Journal of Hematology</i> , 2018 , 93, E61-E64	7.1	23
39	CSF3R-mutated chronic neutrophilic leukemia: long-term outcome in 19 consecutive patients and risk model for survival. <i>Blood Cancer Journal</i> , 2018 , 8, 21	7	17
38	Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases. <i>American Journal of Hematology</i> , 2021 , 96, 781-789	7.1	17
37	MPL-mutated essential thrombocythemia: a morphologic reappraisal. <i>Blood Cancer Journal</i> , 2018 , 8, 1217		13
36	Chronic neutrophilic leukemia: 2020 update on diagnosis, molecular genetics, prognosis, and management. <i>American Journal of Hematology</i> , 2020 , 95, 212-224	7.1	12
35	Chronic neutrophilic leukemia: new science and new diagnostic criteria. <i>Blood Cancer Journal</i> , 2018 , 8, 19	7	11
34	Novel germline mutations in the calreticulin gene: implications for the diagnosis of myeloproliferative neoplasms. <i>Journal of Clinical Pathology</i> , 2016 ,	3.9	9
33	Driver mutations in primary myelofibrosis and their implications. <i>Current Opinion in Hematology</i> , 2018 , 25, 129-135	3.3	8
32	Mutations and thrombosis in essential thrombocythemia. <i>Blood Cancer Journal</i> , 2021 , 11, 77	7	8
31	A population-based study of chronic neutrophilic leukemia in the United States. <i>Blood Cancer Journal</i> , 2020 , 10, 68	7	7
30	JAK2 unmutated erythrocytosis: current diagnostic approach and therapeutic views. <i>Leukemia</i> , 2021 , 35, 2166-2181	10.7	7

29	Extreme thrombocytosis in low-risk essential thrombocythemia: Retrospective review of vascular events and treatment strategies. <i>American Journal of Hematology</i> , 2021 , 96, E182-E184	7.1	6
28	Phenotypical differences and thrombosis rates in secondary erythrocytosis versus polycythemia vera. <i>Blood Cancer Journal</i> , 2021 , 11, 75	7	6
27	Young platelet millionaires with essential thrombocythemia. <i>American Journal of Hematology</i> , 2021 , 96, E93-E95	7.1	5
26	Decreased survival and increased rate of fibrotic progression in essential thrombocythemia chronicled after the FDA approval date of anagrelide. <i>American Journal of Hematology</i> , 2019 , 94, 5-9	7.1	3
25	Serum erythropoietin levels in essential thrombocythemia: phenotypic and prognostic correlates. <i>Blood Cancer Journal</i> , 2018 , 8, 118	7	3
24	Determinants of long-term outcome in type 1 calreticulin-mutated myelofibrosis. <i>Leukemia</i> , 2019 , 33, 780-785	10.7	2
23	The impact of sex on disease phenotype and prognostic thresholds of anemia in myelodysplastic syndromes. <i>American Journal of Hematology</i> , 2018 , 93, E164-E167	7.1	1
22	Chronic neutrophilic leukemia: 2022 update on diagnosis, genomic landscape, prognosis, and management.. <i>American Journal of Hematology</i> , 2022 ,	7.1	1
21	3,023 Mayo Clinic Patients with Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups. <i>Blood</i> , 2018 , 132, 3035-3035	2.2	1
20	Mutations and Thrombosis in Essential Thrombocythemia and Polycythemia Vera: Mayo-Careggi Alliance Study. <i>Blood</i> , 2018 , 132, 3040-3040	2.2	1
19	Secondary Erythrocytosis Is Phenotypically Distinct from Polycythemia Vera but Associated with Comparable Rates of Thrombosis at Diagnosis. <i>Blood</i> , 2020 , 136, 4-7	2.2	1
18	Risk of infection in MPN patients in the era of Covid-19: A prospective multicenter study of 257 patients from the CML-MPN Quebec Research Group. <i>American Journal of Hematology</i> , 2021 , 96, E200-E203	7.1	1
17	Cytogenetic abnormalities in essential thrombocythemia: Clinical and molecular correlates and prognostic relevance in 809 informative cases.. <i>Blood Cancer Journal</i> , 2022 , 12, 44	7	1
16	Myeloproliferative neoplasms - a global view.. <i>British Journal of Haematology</i> , 2022 ,	4.5	1
15	A Globally Applicable "Triple AAA" Risk Model for Essential Thrombocythemia Based on Age, Absolute Neutrophil Count, and Absolute Lymphocyte Count. <i>Blood</i> , 2021 , 138, 238-238	2.2	0
14	A population-based study of outcomes in polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the United States from 2001 to 2015: Comparison with data from a Mayo Clinic single institutional series. <i>American Journal of Hematology</i> , 2021 , 96, E464-E468	7.1	0
13	Current Management of Chronic Neutrophilic Leukemia. <i>Current Treatment Options in Oncology</i> , 2021 , 22, 59	5.4	0
12	Genetic predictors of response to specific drugs in primary myelofibrosis. <i>Blood Cancer Journal</i> , 2018 , 8, 120	7	0

11	Cytogenetics in Essential Thrombocythemia: Phenotype and Molecular Correlates and Prognostic Relevance in 818 Informative Cases. <i>Blood</i> , 2021 , 138, 3629-3629	2.2
10	Patterns of Care and Outcomes in Adolescents and Young Adults with Myeloproliferative Neoplasms: A Multicenter Population-Based Study. <i>Blood</i> , 2021 , 138, 3650-3650	2.2
9	The 1.5 Million Platelet Count Threshold in Essential Thrombocythemia: Phenotype and Genotype Correlates and Relevance to Vascular Events. <i>Blood</i> , 2021 , 138, 3630-3630	2.2
8	Predictors of Spleen and Anemia Response to Specific Drugs in Primary Myelofibrosis. <i>Blood</i> , 2018 , 132, 4300-4300	2.2
7	Serum Erythropoietin Levels in Essential Thrombocythemia: Phenotypic and Prognostic Correlates. <i>Blood</i> , 2018 , 132, 3034-3034	2.2
6	The Germline JAK2 GGCC (46/1) Haplotype and Survival Among 414 Molecularly-Annotated Patients with Primary Myelofibrosis. <i>Blood</i> , 2018 , 132, 1761-1761	2.2
5	Decreased Survival and Increased Rate of Fibrotic Progression in Essential Thrombocythemia Chronically after the FDA Approval Date of Anagrelide. <i>Blood</i> , 2018 , 132, 4287-4287	2.2
4	Determinants of Long-Term Outcome in Type 1/like Calreticulin-Mutated Myelofibrosis. <i>Blood</i> , 2018 , 132, 1767-1767	2.2
3	Myeloproliferative Neoplasms in Young Patients: The Mayo Clinic Experience with 361 Cases Age 40 Years or Younger. <i>Blood</i> , 2018 , 132, 3033-3033	2.2
2	MPL-Mutated Essential Thrombocythemia: A Morphologic Reappraisal. <i>Blood</i> , 2018 , 132, 3036-3036	2.2
1	Risk Factors for Leukemic Transformation Among 1,306 Patients with Primary Myelofibrosis: Mutations Predict Early Events. <i>Blood</i> , 2018 , 132, 3044-3044	2.2